SCHEMBL625829

SCHEMBL625829

CN1CN=c2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)=C1N

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 6/20 0.57
P2RX3 P56373 5/20 0.57
P2RX1 P51575 3/20 0.57
ENPP1 P22413 2/20 0.57
P2RX4 Q99571 2/20 0.57
P2RY6 Q15077 1/20 0.57
P2RY11 Q96G91 1/20 0.57
RNASEL Q05823 5/20 0.56
P2RY12 Q9H244 1/20 0.55
P2RX2 Q9UBL9 3/20 0.55
P2RY2 P41231 2/20 0.55
SRC P12931 1/20 0.55
ALDH1A1 P00352 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
MACROD2 A1Z1Q3 1/20 0.52
SIRT6 Q8N6T7 1/20 0.52
MACROD1 Q9BQ69 1/20 0.52
TRPM2 O94759 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2449672 0.91 ATIC (0.56) P2RY1P2RX3P2RY11RNASELP2RY2
SCHEMBL1062371 0.88 POLB (0.49) P2RY1P2RX3P2RX1ENPP1P2RX4
SCHEMBL2448088 0.87 P2RY1 (0.48) P2RY1ENPP1P2RY11P2RY12
SCHEMBL4377679 0.84 RNASEL (0.51) P2RY1P2RX3P2RX1ENPP1P2RX4
SCHEMBL3512412 0.83 NT5E (0.53) P2RY1P2RX3ENPP1P2RX4P2RY6
SCHEMBL264616 0.81 ATIC (0.52) P2RY1P2RY6P2RY11RNASELP2RY2
SCHEMBL6704190 0.81 ATIC (0.57) P2RY1P2RX3P2RX1P2RX4P2RY11
SCHEMBL5721746 0.81 P2RX3 (0.52) P2RY1P2RX3P2RX1ENPP1P2RX4
SCHEMBL8840654 0.80 ATIC (0.52) P2RY1P2RY6P2RY11RNASELP2RY2
SCHEMBL5317002 0.79 TP53 (0.50) ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12460204-B2 Artificial nucleic acid molecules for improved protein or peptide expression CureVac SE (DE) 2025-11-04 US claimed
US-20240415958-A1 MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE TRANSLATE BIO INC (US) 2024-12-19 US claimed
US-11998601-B2 Messenger RNA therapy for treatment of articular disease TRANSLATE BIO, INC. (US) 2024-06-04 US claimed
US-20220372158-A1 RNA-CODED ANTIBODY CUREVAC AG (DE) 2022-11-24 US claimed
US-11421038-B2 RNA-coded antibody CUREVAC AG (DE) 2022-08-23 US claimed
US-20220145295-A1 ENZYMATIC RNA SYNTHESIS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-05-12 US claimed
EP-3115064-B1 RNA-CODED ANTIBODY CUREVAC AG (DE) 2021-11-24 EP claimed
US-11110156-B2 Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen CUREVAC AG (DE) 2021-09-07 US claimed
US-20210060181-A1 NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED THERAPEUTIC PROTEIN CUREVAC AG (DE) 2021-03-04 US claimed
US-20210060175-A1 METHODS OF IMMUNOSTIMULATION WITH COMPLEXES OF RNA AND CATIONIC CARRIERS CUREVAC AG (DE) 2021-03-04 US claimed
US-20160152706-A1 RNA-CODED ANTIBODY CUREVAC AG (DE) 2016-06-02 US claimed
US-20160145346-A1 RNA-CODED ANTIBODY CUREVAC AG (DE) 2016-05-26 US claimed
US-9234013-B2 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded protein CUREVAC AG (DE) 2016-01-12 US claimed
US-20150184195-A1 ARTIFICIAL NUCLEIC ACID MOLECULES CUREVAC GMBH (DE) 2015-07-02 US claimed
US-20150165006-A1 NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED ALLERGENIC ANTIGEN OR AN AUTOIMMUNE SELF-ANTIGEN Cure GmbH (DE) 2015-06-18 US claimed
US-20150093413-A1 NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN CUREVAC GMBH (DE) 2015-04-02 US claimed
US-20140170689-A1 Modified Diguanylate Cyclase-Phosphodiesterase and Method for Enzymatic Production of Cyclic-diGMP THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2014-06-19 US claimed
US-20130195867-A1 RNA-CODED ANTIBODY CUREVAC GMBH (DE) 2013-08-01 US claimed
US-20100189729-A1 RNA-CODED ANTIBODY CURVAC GMBH (DE) 2010-07-29 US claimed
US-20100047261-A1 BASE-MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN CUREVAC GMBH (DE) 2010-02-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150093413-A1 NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN HNRNPH3, PARG, CPSF6 P2RY1 1936/4885P2RX3 1754/4885P2RX1 1816/4885
US-20160145346-A1 RNA-CODED ANTIBODY TRDMT1, NSUN3, POLRMT P2RY1 3643/4885P2RX3 2501/4885P2RX1 2801/4885
US-20210060181-A1 NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED THERAPEUTIC PROTEIN HNRNPH3, CPSF6, HNRNPL P2RY1 2048/4885P2RX3 1904/4885P2RX1 2131/4885
US-20160152706-A1 RNA-CODED ANTIBODY TRDMT1, NSUN3, POLRMT P2RY1 3643/4885P2RX3 2501/4885P2RX1 2801/4885
US-20150165006-A1 NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED ALLERGENIC ANTIGEN OR AN AUTOIMMUNE SELF-ANTIGEN NASP, H1-5, PARG P2RY1 1538/4885P2RX3 1492/4885P2RX1 1585/4885
US-12460204-B2 Artificial nucleic acid molecules for improved protein or peptide expression RNMT, NSUN3, RNGTT P2RY1 2831/4885P2RX3 2043/4885P2RX1 2554/4885
US-20100047261-A1 BASE-MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN RNMT, RNASE1, NSUN3 P2RY1 4557/4885P2RX3 4449/4885P2RX1 4424/4885
US-20240415958-A1 MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE NSUN3, RNMT, TRDMT1 P2RY1 3509/4885P2RX3 2826/4885P2RX1 3258/4885
US-11998601-B2 Messenger RNA therapy for treatment of articular disease NSUN3, RNMT, TRDMT1 P2RY1 3509/4885P2RX3 2826/4885P2RX1 3258/4885
US-11110156-B2 Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen HNRNPH3, HNRNPL, CPSF6 P2RY1 1808/4885P2RX3 1525/4885P2RX1 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.